Van de Kar L D, Rittenhouse P A, Li Q, Levy A D
Department of Pharmacology, Loyola University of Chicago, IL 60153, USA.
Behav Brain Res. 1996;73(1-2):203-8. doi: 10.1016/0166-4328(96)00097-6.
Drugs that, directly or indirectly produce activation of serotonin (5-HT) receptors increase plasma concentrations of both prolactin and renin. The serotonergic regulation of prolactin and renin secretion share several common characteristics. Serotonergic neurons originating in the dorsal raphe and terminating in the hypothalamus stimulate the secretion of both prolactin and renin. Destruction of cells in the hypothalamic paraventricular nucleus (PVN) inhibits both the prolactin and renin responses to 5-HT agonists and 5-HT-releasing drugs. Activation of 5-HT2 receptors increases the secretion of both prolactin and renin, while activation of other 5-HT receptor subtypes has differential effects on these hormones. However, there are also differences between the serotonergic mechanisms that regulate the secretion of prolactin and renin. Activation of 5-HT1A receptors increases the secretion of prolactin but not of renin. In addition, activation of peripheral 5-HT2 receptors stimulates the secretion of renin, while activation of peripheral 5-HT3 receptors increases plasma levels of prolactin but not renin. In humans, the effect of 5-HT-releasing drugs and 5-HT agonists on plasma prolactin concentrations has been studied to a greater extent than effects on most other hormones. In contrast, the renin response to 5-HT agonists and 5-HT releasers has not been well characterized in humans. Because of the important role of the renin-angiotensin system in cardiovascular regulation, studies on the serotonergic regulation of renin release in humans could increase our understanding of cardiovascular disorders associated with altered serotonergic function. Examples include anxiety and consequences of cocaine abuse. In conclusion, comparing the serotonergic regulation of prolactin and renin secretion indicates similarities that might shed light on common brain mechanisms that regulate neuroendocrine function.
直接或间接激活5-羟色胺(5-HT)受体的药物会使催乳素和肾素的血浆浓度升高。催乳素和肾素分泌的5-羟色胺能调节具有几个共同特征。起源于中缝背核并终止于下丘脑的5-羟色胺能神经元会刺激催乳素和肾素的分泌。下丘脑室旁核(PVN)中的细胞被破坏会抑制催乳素和肾素对5-HT激动剂和5-HT释放药物的反应。5-HT2受体的激活会增加催乳素和肾素的分泌,而其他5-HT受体亚型的激活对这些激素有不同的影响。然而,调节催乳素和肾素分泌的5-羟色胺能机制之间也存在差异。5-HT1A受体的激活会增加催乳素的分泌,但不会增加肾素的分泌。此外,外周5-HT2受体的激活会刺激肾素的分泌,而外周5-HT3受体的激活会增加催乳素的血浆水平,但不会增加肾素的水平。在人类中,与对大多数其他激素的影响相比,5-HT释放药物和5-HT激动剂对血浆催乳素浓度的影响得到了更广泛的研究。相比之下,5-HT激动剂和5-HT释放剂对肾素的反应在人类中尚未得到很好的表征。由于肾素-血管紧张素系统在心血管调节中起着重要作用,对人类肾素释放的5-羟色胺能调节的研究可能会增加我们对与5-羟色胺能功能改变相关的心血管疾病的理解。例子包括焦虑和可卡因滥用的后果。总之,比较催乳素和肾素分泌的5-羟色胺能调节表明了一些相似之处,这些相似之处可能有助于揭示调节神经内分泌功能的共同脑机制。